Groowe Groowe BETA / Newsroom
⏱ News is delayed by 15 minutes. Sign in for real-time access. Sign in

Global Anti-Obesity Drugs Market Report 2026: Set to Reach $106.5 Billion by 2035 as GLP-1 Therapies Transform Obesity Care

globenewswire.com
OPK OPKO Health is jointly developing an oral GLP-1/glucagon agonist (OPK-88008) with Entera Bio, indicating potential in the growing anti-obesity drug market. However, the article does not provide specific performance details for OPKO. NVO Novo Nordisk is a market leader in GLP-1 therapies for obesity, experiencing high demand that exceeds production capacity. This indicates strong market position and significant growth potential, despite manufacturing constraints. LLY Eli Lilly is a leading player in the anti-obesity drug market, with therapies like tirzepatide showing significant weight-loss outcomes. High demand and investment underscore its strong market position and growth prospects. TEVA Teva's introduction of generic liraglutide indicates growing competition in the anti-obesity drug market. This suggests market presence but doesn't provide specific performance metrics or future outlook for Teva.

Global Anti-Obesity Drugs Market Report 2026: Set to Reach $106.5 Billion by 2035 as GLP-1 Therapies Transform Obesity Care Dublin, Sept. 01, 2026 (GLOBE NEWSWIRE) -- The "Anti-Obesity Drugs Market by Type of Molecule, Type of Drug, Active Compound, Mechanism of Action, Type of Agonist, Action Pathway, Route of Administration, Distribution Channel, Geographical Regions, and Key Players - Trends and Forecast Till 2035" has been added to ResearchAndMarkets.com's offering.

The global anti-obesity drugs market is projected to grow from USD 45.1 billion in 2026 to USD 106.5 billion by 2035, representing a compound annual growth rate of approximately 10.0% during the forecast period. Rising obesity prevalence, expanding clinical evidence, next-generation drug development and increasing access to prescription weight-loss therapies are expected to support sustained market expansion.

Anti-Obesity Drugs Market Growth and Trends

Obesity remains a major global public health challenge. Data compiled by the NCD Risk Factor Collaboration indicates that more than one billion people worldwide are living with obesity, including approximately 880 million adults and 159 million children and adolescents. The association between obesity and diabetes, cardiovascular disease, renal complications and several cancers is intensifying demand for effective pharmacological treatments.

GLP-1 receptor agonists have become a defining force in the anti-obesity drugs market. Therapies containing semaglutide and tirzepatide have delivered significant weight-loss outcomes, accelerating physician adoption and increasing investment across the pharmaceutical industry. Clinical findings are also broadening the role of these treatments beyond weight management. The SELECT cardiovascular outcomes trial, for example, found that semaglutide reduced the risk of major adverse cardiovascular events by 20% in overweight or obese adults with established cardiovascular disease.

The transition from injectable treatments to oral anti-obesity drugs represents another important market opportunity. Oral therapies may reduce cold-chain requirements, distribution costs and barriers related to injectable administration. OPKO Health and Entera Bio are jointly developing OPK-88006, an oral, once-daily dual GLP-1/glucagon agonist. Other oral candidates, including orforglipron and ECC5004, could further improve treatment access following regulatory approval.

Key Anti-Obesity Drugs Market Growth Drivers

Market Challenges

High research and development costs remain a significant barrier for anti-obesity drug developers. Long-term clinical studies are required to demonstrate durable weight loss, cardiometabolic benefits and acceptable safety profiles. Stringent regulatory review can further increase development timelines and commercialization costs.

Manufacturing capacity is another major constraint. Novo Nordisk and Eli Lilly have experienced supply pressure as demand for GLP-1 therapies has exceeded available production capacity. Market adoption may also be affected by adverse events, long-term safety considerations and patient perceptions. Continued post-marketing surveillance, transparent clinical communication and physician education will remain essential.

Competitive Landscape and Emerging Opportunities

Eli Lilly and Novo Nordisk currently lead the global anti-obesity drugs market, but competition is expanding. Roche has announced a USD 2 billion investment to increase US manufacturing capacity for obesity treatments, while Teva's introduction of generic liraglutide indicates growing competition across branded and generic products.

Mergers and acquisitions are also supporting geographic expansion. Voy's acquisition of India-based online weight-management platform EarlyFit illustrates how companies can gain faster entry into large, underpenetrated markets through established digital distribution networks.

Biologics account for the largest share of the development pipeline, with GLP-1-based products maintaining a prominent position. Nevertheless, oral therapies and small-molecule candidates could reshape the competitive landscape by improving convenience, scalability and access in cost-sensitive markets.

Key Market Segmentation Insights

Regional Anti-Obesity Drugs Market Outlook

North America currently generates the largest share of global anti-obesity drug revenue, supported by high obesity prevalence, established healthcare infrastructure and comparatively favorable reimbursement pathways. The United States remains a major center for clinical development, commercialization and manufacturing investment.

Asia-Pacific is projected to register the fastest regional growth through 2035. Rising obesity rates, urbanization, greater healthcare spending and expanding treatment access in China, India, Japan, South Korea and Australia are creating substantial opportunities. The report also assesses Europe and Latin America, including Germany, the UK, France, Italy, Spain, Brazil and Argentina.

Leading Companies in the Anti-Obesity Drugs Market

Research Coverage

The report provides anti-obesity drugs market sizing and opportunity analysis by molecule type, drug type, active compound, mechanism of action, agonist type, action pathway, route of administration, distribution channel and geography. It also evaluates the competitive landscape, company pipelines, strategic initiatives, manufacturing expansion, partnerships, acquisitions and the market impact of major drivers, restraints, opportunities and challenges.

The research incorporates perspectives from executives, endocrinologists, medical researchers, academic specialists and pharmaceutical industry leaders in the United States, Canada and Denmark. It addresses the current and projected market size, leading segments, fastest-growing regions, competitive positioning and the expected impact of oral anti-obesity therapies.

Report Benefits

With obesity prevalence continuing to rise and clinical innovation accelerating, the global anti-obesity drugs market is positioned for substantial growth through 2035. Expanding indications, oral drug development, manufacturing investment and competition among major pharmaceutical companies are expected to transform obesity treatment and create significant commercial opportunities worldwide.

For more information about this report visit https://www.researchandmarkets.com/r/ann7ka

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.